Biotech Values

[DewDiligence]

Re: GTCB

>>I expect the fact that the PRs will be bundled for the three items means that not all will be positive.<<

That’s a reasonable inference if in fact there is a single, catchall PR. But I don’t think such an outcome is clear-cut, based on what Mr. Newberry said.

To review, the items on which shareholders are due an update by year-end are:

1. Status of the answers to the EMEA’s ATryn questions. Of course, we want to the update to be that that the answers have been duly submitted. Even better would be a tad of color regarding the content of the answers, but I am not expecting that.

2. Terms of a partnership deal for ATryn. (I think this is the item where further slippage is most likely.)

3. Filing of an IND amendment with the FDA in order to conduct a pivotal ATryn trial in the U.S.